Purpose: To describe a case of corneal ulceration associated with dupilumab use for atopic dermatitis. Observations: A patient developed an inflammatory corneal ulcer 3 weeks after starting bi-weekly intravenous dupilumab therapy. Symptoms resolved with topical prednisolone and discontinuation of the systemic therapy with dupilumab. Conclusion and importance: Dupilumab is known to cause ocular surface inflammation, but we report a novel association between dupilumab use and potentially sight-threatening corneal ulceration.
|Original language||English (US)|
|Journal||American Journal of Ophthalmology Case Reports|
|State||Published - Sep 2020|
- Atopic dermatitis
- Corneal ulceration
ASJC Scopus subject areas